Avista Capital Partners Investment Firm Overview

Avista Capital Partners is a leading private equity investment firm. They specialize in investing in middle-market companies across various industries. Their investment strategy focuses on acquiring companies with strong growth potential.

Avista Capital Partners was founded in 2005 and is headquartered in New York City. The firm has a dedicated team of investment professionals with expertise in various sectors.

Avista Capital Partners was founded in 2005 by Steven Webster, Thompson Dean, and David Burgstahler as a spinoff from Credit Suisse's private equity arm DLJ Merchant Banking Partners.

The firm was one of several private equity groups spun out from leading investment banks at the same time, including JPMorgan Chase's CCMP Capital, Citigroup's Court Square Capital Partners, Deutsche Bank's MidOcean Partners, and Morgan Stanley's Metalmark Capital.

Avista's first fund closed in 2007 with $2 billion in commitments, including a commitment from Credit Suisse, which was not made by fellow spin-off Diamond Castle.

The firm's second fund closed with $1.8 billion in commitments, lower than its original target of $2.5 to $3 billion, due to changes in North American alternative investment strategies.

Avista's third fund closed in 2013 with $1.4 billion in commitments, and the firm began raising its fourth fund in 2016 with UBS acting as the placement agent.

The fourth fund focused exclusively on healthcare and closed in 2017 with $775 million in committed capital.

In 2017, Avista's former energy team spun out and formed AEC Partners, which began raising its first fund that same year.

Avista's fifth fund closed in 2021 with $1.2 billion in capital, exceeding its original target of $775 million.

Avista Capital Partners has made several notable investments and acquisitions in the healthcare industry.

The firm acquired Trillium Health Care Products from New Water Capital, expanding its portfolio in the healthcare sector.

Avista Capital Partners also acquired Taconic Biosciences, a leading provider of genetically engineered research models and services. Founded in 1952, Taconic specializes in murine models for use in drug discovery research and non-clinical safety testing.

The acquisition of Taconic represents Avista's ninth investment in the outsourced pharma services sector, a testament to the value and growth potential it sees in the space.

Avista Capital Partners entered into definitive documentation to acquire Probo Medical, a global leader in the medical imaging equipment market, from Varsity Healthcare Partners.

Avista Capital Partners has a long history of success, with a founding date of 2003. The firm was established by a team of experienced investment professionals.

Avista Capital Partners has a strong track record of investing in the healthcare sector, with a significant portion of its portfolio dedicated to this area.

Avista Capital Partners has received significant media attention over the years.

They have been featured in prominent publications such as Forbes, Bloomberg, and Private Equity International.

Avista Capital Partners has also been recognized as one of the top 20 private equity firms in the world by Private Equity International.

Their investment strategy and expertise have been covered in various industry reports and studies.